Iganidipine
(Synonyms: 伊加地平) 目录号 : GC32537
Iganidipine是一种钙离子通道拮抗剂。
Cas No.:119687-33-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Iganidipine is a Ca2+ antagonist.
Iganidipine (0.03% solution) significantly increases optic nerve head (ONH) tissue blood velocity (NBONH) by 8 to 10% in treated eyes after a single administration (p<0.05) or by 18 to 35% after 7-, 14-, or 21-day twicedaily administration in rabbits (p<0.05). In monkeys, 0.03% and 0.1% Iganidipine significantly increases NBONH in treated eyes by 20 and 41% after 7-day (p<0.05) twice-daily administration, respectively[1].
[1]. Ishii K, et al. Iganidipine, a new water-soluble Ca2+ antagonist: ocular and periocular penetration after instillation. Invest Ophthalmol Vis Sci. 2003 Mar;44(3):1169-77.
Animal experiment: | Monkeys[1] Five adult cynomolgus monkeys (age, 5-8 years; weight, 3-5 kg; sex, 5 males) are used. All examinations are performed with the monkeys sitting in a modified monkey chair. On the first experimental day, after general anesthesia is induced by Ketamine hydrochloride at a dose of 8 to 10 mg/kg intramuscularly, pupil dilation is induced with one drop of Tropicamide in both eyes. The NBONH, IOP, blood pressure, pulse rate, SaO2, and body temperature are measured at 9AM. Starting on the 2nd experimental day, Iganidipine (0.03% or 0.1%, 30 mL) is administered in one randomly chosen eye and vehicle solution into the other eye twice daily at 8AM and 8PM for 7 days. At 9AM on the 8th experimental day, the same measurements are repeated after general anesthesia and bilateral pupil dilation. After a 4-week interval, a second series of experiments is performed using a different Iganidipine concentration according to the same time schedule. |
References: [1]. Ishii K, et al. Iganidipine, a new water-soluble Ca2+ antagonist: ocular and periocular penetration after instillation. Invest Ophthalmol Vis Sci. 2003 Mar;44(3):1169-77. | |
| Cas No. | 119687-33-1 | SDF | |
| 别名 | 伊加地平 | ||
| Canonical SMILES | O=C(C1=C(C)NC(C)=C(C(OC)=O)C1C2=CC=CC([N+]([O-])=O)=C2)OCC(C)(C)CN3CCN(CC=C)CC3 | ||
| 分子式 | C28H38N4O6 | 分子量 | 526.62 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.8989 mL | 9.4945 mL | 18.989 mL |
| 5 mM | 0.3798 mL | 1.8989 mL | 3.7978 mL |
| 10 mM | 0.1899 mL | 0.9495 mL | 1.8989 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet